Plunkett Research Online: Lyell Immunopharma Inc

LYELL IMMUNOPHARMA INC (LYEL:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Lyell Immunopharma Inc is a T cell reprogramming company dedicated towards the mastery of T cells to eradicate solid tumors. Its pipeline includes CARs (Chimeric antigen receptors), TILs (Tumor-infiltrating lymphocytes), and TCRs (T cell receptors)......



Lyell Immunopharma Inc
Ticker: LYEL
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 650 695-0677
Fax:
Address: 201 Haskins Way
South San Francisco, CA 94080 United States

Map
Types Of Business
Industry Ranks

Industry NAICS code:

Pharmaceuticals, Biopharmaceuticals, Generics and Drug Manufacturing
Contacts Description
Lynn SeelyCEO/Director/President
Charles NewtonCFO/Chief Accounting Officer
See More
Lyell Immunopharma Inc is a T cell reprogramming company dedicated towards the mastery of T cells to eradicate solid tumors. Its pipeline includes CARs (Chimeric antigen receptors), TILs (Tumor-infiltrating lymphocytes), and TCRs (T cell receptors)......See More See More

Auditor: Ernst & Young LLP
Legal Advisor:
$USD, In whole numbers,
except marked * or %
20232022202120202019
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and Affiliates Top Salaries
NameTitleSalary (US$)Bonus (US$)
Other Thoughts Corporate Culture

Apparent Female Officers or Directors: